![Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine | Business Wire Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine | Business Wire](https://mms.businesswire.com/media/20190821005238/en/739014/22/teva_RGB_JPEG.jpg)
Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine | Business Wire
![Public Assessment Report Decentralised Procedure … / public-assessment-report-decentralised-procedure.pdf / PDF4PRO Public Assessment Report Decentralised Procedure … / public-assessment-report-decentralised-procedure.pdf / PDF4PRO](https://pdf4pro.com/cache/preview/5/9/b/0/9/3/8/f/thumb-59b0938f363360a18e108e0c48445a2f.jpg)
Public Assessment Report Decentralised Procedure … / public-assessment-report-decentralised-procedure.pdf / PDF4PRO
![Teva Pharmaceutical (TEVA) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow (NYSE:TEVA) | Seeking Alpha Teva Pharmaceutical (TEVA) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow (NYSE:TEVA) | Seeking Alpha](https://static2.seekingalpha.com/uploads/sa_presentations/360/50360/slides/10.jpg?1579019835)